President Donald Trump’s tariff policies have caused uncertainty across various industries, including pharmaceuticals, even if they haven’t directly impacted them yet. Eli Lilly (LLY), a leading pharma stock, could face challenges such as rising raw material costs and potential retaliatory tariffs, which may compress profit margins in the near term. Despite these concerns, Lilly’s long-term outlook remains positive due to growth in blockbuster drugs like Mounjaro and Zepbound, along with emerging opportunities in the Alzheimer’s market, suggesting it may still be a good time to invest with a long-term perspective.
